Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of AGMB-129 Tablet vs Capsule
NCT06397508Phase 1Completed
- Sponsor
- Agomab Therapeutics
- Start
- Apr 2024
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ontunisertib in Crohn's disease (6 arms), sponsored by Agomab Therapeutics. Primary endpoints: Maximum Observed Plasma Concentration (Cmax) for AGMB-129 at Day 3, Maximum Observed Plasma Concentration (Cmax) for MET-158 at Day 3 and 7 more. Started Apr 2024; status: completed.
02
Drugs
ontunisertib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06397508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06397508.